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ABSTRACT
Introduction: Daratumumab, a human IgG
monoclonal antibody targeting CD38, has
demonstrated activity as monotherapy and in
combination with standard-of-care regimens in
multiple myeloma. Population pharmacoki-
netic analyses were conducted to determine the
pharmacokinetics of intravenous daratumumab
in combination therapy versus monotherapy,
evaluate the effect of patient- and disease-
related covariates on drug disposition, and
examine the relationships between daratu-
mumab exposure and efficacy/safety outcomes.
Methods: Four clinical studies of daratumumab
in combination with lenalidomide/dexametha-
sone (POLLUX and GEN503); bortezomib/dex-
amethasone (CASTOR); pomalidomide/
dexamethasone, bortezomib/thalidomide/dex-
amethasone, and bortezomib/melphalan/pred-
nisone (EQUULEUS) were included in the
analysis. Using various dosing schedules, the
majority of patients (684/694) received daratu-
mumab at a dose of 16 mg/kg. In GEN503,
daratumumab was administered at a dose of
2 mg/kg (n = 3), 4 mg/kg (n = 3), 8 mg/kg
(n = 4), and 16 mg/kg (n = 34). A total of
650 patients in EQUULEUS (n = 128), POLLUX
(n = 282), and CASTOR (n = 240) received
daratumumab 16 mg/kg. The exposure–efficacy
Enhanced digital features To view enhanced digital
features for this article go to https://doi.org/10.6084/
m9.figshare.7165493.
Electronic supplementary material The online
version of this article (https://doi.org/10.1007/s12325-
018-0815-9) contains supplementary material, which is
available to authorized users.
X. S. Xu (&)  J. Schecter
Janssen Research & Development, LLC, Raritan, NJ,
USA
e-mail: sxu26@its.jnj.com
M. A. Dimopoulos
National and Kapodistrian University of Athens,
Athens, Greece
P. Sonneveld
Department of Hematology, Erasmus MC,
Rotterdam, The Netherlands
P. J. Ho
Royal Prince Alfred Hospital, Camperdown,
New South Wales, Australia
A. Belch
Cross Cancer Institute, Edmonton, AB, Canada
M. Leiba
Assuta Ashdod University Hospital, Faculty of
Health Sciences, Ben Gurion University of the
Negev, Beersheba, Israel
M. Capra
Instituto do Cancer, Hospital Ma˜e de Deus,
Porto Alegre, Brazil
D. Gomez
Hospital Universitario de la UANL, Monterrey,
Nuevo Leon, Mexico
Adv Ther
https://doi.org/10.1007/s12325-018-0815-9
and exposure–safety relationships examined
progression-free survival (PFS) and selected
adverse events (infusion-related reactions;
thrombocytopenia, anemia, neutropenia, lym-
phopenia, and infections), respectively.
Results: Pharmacokinetic profiles of daratu-
mumab were similar between monotherapy and
combination therapy. Covariate analysis iden-
tified no clinically important effects on daratu-
mumab exposure, and no dose adjustments
were recommended on the basis of these fac-
tors. Maximal clinical benefit on PFS was
achieved for the majority of patients (approxi-
mately 75%) at the 16 mg/kg dose. No apparent
relationship was observed between daratu-
mumab exposure and selected adverse events.
Conclusion: These data support the recom-
mended 16 mg/kg dose of daratumumab and
the respective dosing schedules in the POLLUX
and CASTOR pivotal studies.
Funding: Janssen Research & Development.
Keywords: CD38; Daratumumab; Pharmaco-
kinetics; Multiple myeloma; Oncology
INTRODUCTION
Despite recent advancements in treatment
strategies for multiple myeloma (MM), out-
comes remain poor and treatment options are
limited for patients who relapse following
therapy with a proteasome inhibitor (PI) and an
immunomodulatory drug (IMiD), or those who
are refractory to these agents [1, 2]. Daratu-
mumab is a human monoclonal antibody that
targets CD38 and induces anti-myeloma activ-
ity through on-tumor and immunomodulatory
mechanisms of action [3–8]. Clinical studies of
daratumumab monotherapy (GEN501 and SIR-
IUS) demonstrated deep and durable responses
in patients with heavily treated relapsed or
relapsed and refractory MM [9, 10]. Clinical
and pharmacokinetics (PK) data from these
studies led to the approval of daratumumab
monotherapy in many countries worldwide [11]
and established the recommended dose
(16 mg/kg actual body weight) and dosing
schedule (once weekly for 8 weeks, every
2 weeks for 16 weeks, and every 4 weeks there-
after) for treatment [10, 12–14]. In a pooled
analysis of GEN501 and SIRIUS, daratumumab
monotherapy (16 mg/kg) was well tolerated,
and patients with heavily treated MM achieved
an overall response rate (ORR) of 31.1% [10, 15].
Recent studies have indicated that there is a
significant benefit to patient outcomes when
daratumumab is combined with various back-
ground therapy regimens. The combination of
daratumumab with lenalidomide and dexam-
ethasone (D-Rd) resulted in an ORR of 81% in
the single-arm phase 1/2 GEN503 study of the
combination in heavily treated patients with
refractory or relapsed and refractory MM [16]. In
the phase 3 POLLUX study, D-Rd elicited a sig-
nificant 63% reduction in disease progression or
death compared with lenalidomide and dex-
amethasone (Rd) alone [17]. Similarly, in the
phase 3 CASTOR study, daratumumab plus
bortezomib and dexamethasone (D-Vd) signifi-
cantly reduced the risk of progression or death
by 61% compared to bortezomib and dexam-
ethasone (Vd) alone in patients with relapsed
and refractory disease treated with a median of
two lines of therapy [18]. On the basis of these
pivotal studies, daratumumab in combination
with Rd or Vd was first approved in the USA and
Europe [19], and subsequently many other
countries, for the treatment of patients with
MM who have received one or more prior lines
of therapy. A recent phase 1 study (EQUULEUS)
of daratumumab in combination with poma-
lidomide and dexamethasone (D-Pd) yielded
promising results, with an ORR of 60%, and
29% of patients who achieved a complete
response or better reached minimal residual
disease negative status at a sensitivity threshold
of 10-5 [20]. On the basis of these findings, D-Pd
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was approved in the USA for patients with MM
who have received at least two prior lines of
therapy including lenalidomide and a protea-
some inhibitor. Recently, daratumumab added
to the standard of care regimen of bortezomib,
melphalan, and prednisone (D-VMP) was
shown to reduce the risk of progression or death
by 50% in transplant-ineligible newly diag-
nosed MM patients [21].
PK data from the monotherapy studies
(GEN501 and SIRIUS) indicate that daratu-
mumab exhibits nonlinear PK consistent with
target-mediated drug disposition [13]. Popula-
tion PK modeling showed that efficacious con-
centrations of daratumumab were achieved
rapidly in patients receiving daratumumab
16 mg/kg via the standard dosing schedule and
were maintained as the frequency of dosing was
reduced [12, 14]. Given the promising efficacy of
daratumumab when combined with other
treatments across all lines of treatment, it is
necessary to understand the PK of daratumumab
when administered as part of a combination
regimen and the relationship of daratumumab
exposure with efficacy and safety.
The purpose of this investigation was to
determine the PK of daratumumab in combi-
nation therapy. Population PK analyses were
performed using data from four clinical studies
of daratumumab combination therapy includ-
ing POLLUX, GEN503, CASTOR, and EQUU-
LEUS. We compared PK of combination
therapies versus daratumumab monotherapy,
evaluated the effect of patient- and disease-re-
lated covariates on drug disposition, and
examined the relationships between daratu-
mumab exposure and safety and efficacy
outcomes.
METHODS
Patients and Study Designs
Population PK analyses were performed on
combined datasets from four clinical studies:
CASTOR (MMY3004; ClinicalTrials.gov identi-
fier, NCT02136134), POLLUX (MMY3003;
NCT02076009), GEN503 (NCT01615029), and
EQUULEUS (MMY1001; NCT01998971), all of
which have been described in detail elsewhere
[16–18, 20]. Key eligibility criteria for each study
are shown in Supplemental Table 1. CASTOR
was a randomized, active-controlled, multicen-
ter, phase 3 study comparing D-Vd to Vd alone
in patients with relapsed or relapsed and
refractory MM [18]. In CASTOR, patients
received daratumumab 16 mg/kg once weekly
for 9 weeks (cycles 1–3), every 3 weeks for
15 weeks (cycles 4–8), and every 4 weeks there-
after (Supplemental Table 2). POLLUX was a
randomized, active-controlled, multicenter,
phase 3 study comparing D-Rd to Rd alone in
patients with relapsed or refractory MM [17]. In
POLLUX, daratumumab 16 mg/kg was admin-
istered once weekly for 8 weeks (cycles 1–2),
then every 2 weeks for 16 weeks (cycles 3–6),
and then every 4 weeks thereafter. GEN503 was
a phase 1/2, open-label, dose-escalation (part 1)
and dose-expansion (part 2) study of D-Rd in
patients with refractory or relapsed and refrac-
tory MM [16]. In part 2 of GEN503, patients
received daratumumab 16 mg/kg on the same
dosing schedule as the POLLUX study. EQUU-
LEUS was a multi-arm, phase 1/2, open-label
study of daratumumab in combination with a
variety of backbone regimens in newly diag-
nosed and relapsed or refractory MM [20].
Dosing schedules were once weekly for 6 weeks
[cycles 1–2 for Vd and bortezomib, thalidomide,
and dexamethasone (VTd); cycle 1 for borte-
zomib, melphalan, and prednisone (VMP)],
then every 3 weeks thereafter, or were consis-
tent with the dosing schedule in POLLUX (Rd),
depending on the combination partners.
In the combined analysis, daratumumab
was administered intravenously to a total of
694 patients using various dosing schedules. A
total of 650 patients in EQUULEUS (n = 128),
POLLUX (n = 282), and CASTOR (n = 240)
received daratumumab 16 mg/kg. In GEN503, a
total of 34 patients received daratumumab
16 mg/kg, while the remaining patients
received daratumumab at doses of 2 mg/kg
(n = 3), 4 mg/kg (n = 3), and 8 mg/kg (n = 4).
Thus, the population PK dataset included 694
patients, 684 of whom received daratumumab
16 mg/kg. Patients who received less than
16 mg/kg of daratumumab were not included in
the efficacy and safety analysis.
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Compliance with Ethics Guidelines
All studies were conducted in accordance with
the International Conference on Harmonisa-
tion Good Clinical Practice guidelines and the
principles of the Declaration of Helsinki, and all
patients provided written informed consent.
Population PK and Exposure–Response
Analysis
Analyses were performed on pooled datasets
from CASTOR, POLLUX, GEN503, and EQUU-
LEUS. In CASTOR, samples were collected
within 2 h prior to and immediately following
daratumumab infusions on day 1 of cycles 1, 3,
6, 9, and 12 (cycles 1–8: 21 days; cycles 9?:
28 days). In POLLUX, samples were collected
within 2 h prior to and immediately following
daratumumab infusions on day 1 of cycles 1, 3,
and 12 (28-day cycles). In both CASTOR and
POLLUX, samples were collected at the end of
treatment and during the follow-up visit. In
GEN503, part 1, samples were collected prior to
and at the end of infusion on all daratumumab
infusion days, at each follow-up visit, and at the
end of treatment visit. In part 2 of GEN503, the
sampling schedule was reduced to day 1 of cycles
1, 3, 6, and 12, and at weeks 4 and 8 after the last
treatment dose. In EQUUELUS, samples from
the D-VMP and D-Pd regimens were collected
within 2 h prior to and at the end of infusion on
days 1 and 22 of cycle 1, day 1 of cycles 2–4, and
weeks 3 and 9 of the follow-up phase (D-VMP:
42-day cycles; D-Pd: 28-day cycles). In the
D-VTd and D-Vd arms of EQUUELUS, samples
were collected within 2 h prior to and at the end
of infusion on day 1 of cycles 1–4 and at weeks 3
and 9 of the follow-up phase (D-VTd and D-Vd:
21-day cycles). Serum daratumumab concentra-
tions were evaluated using a validated enzyme-
linked immunosorbent assay [lower limit of
quantitation (LLOQ) = 0.2 lg/mL; BioAnalytical
Research Corporation Global Central Labora-
tory, Ghent, Belgium; Janssen Research &
Development, LLC, Spring House, PA, USA).
Immunogenicity was analyzed by determining
the presence of anti-daratumumab antibodies. A
population PK model, previously developed
using data from daratumumab monotherapy
studies [14], was used to fit concentration–time
data from the four combination studies. No
direct impact of the background therapies on
the PK of daratumumab was expected given the
lack of overlapping clearance mechanisms for
daratumumab and the co-administered small-
molecule therapies [22–24]. NONMEM 7.2
software (ICON, Dublin, Ireland) was used for
population PK modeling. Software package R
(version 3.1.2) was used for data management,
post-processing, and all other analyses of NON-
MEM runs. PK simulations were run using the
dosing schedules for CASTOR and for POLLUX.
Subgroup analyses were performed to evalu-
ate the relationship between daratumumab
exposure and patient- and disease-related char-
acteristics, including age, race, sex, body
weight, hepatic or renal impairment, type of
myeloma (immunoglobulin [Ig] G versus non-
IgG), baseline Eastern Cooperative Oncology
Group status, number of prior therapies, and
refractory status. The relationship between
daratumumab exposure [maximal pre-infusion
(trough) concentration (Cpre-infusion,max)] and
progression-free survival (PFS) was examined for
the POLLUX and CASTOR studies in which PFS
was the primary endpoint. The relationship
between Cpre-infusion,max and adverse events
(AEs) of interest, selected because of their fre-
quency in anti-myeloma treatment (i.e., inci-
dence of thrombocytopenia, anemia,
neutropenia, lymphopenia, and infections), was
examined by treatment regimen [i.e., D-Rd
(combined data from POLLUX and GEN503),
D-Vd (CASTOR), and D-Pd (EQUULEUS)]. To
evaluate the relationship between the incidence
of infusion-related reactions (IRRs) and daratu-
mumab exposure, the predicted end-of-infusion
concentration after the first infusion (Cmax,1st)
was used because the majority of IRRs occurred
during the first infusion.
Cox proportional hazard regression models,
implemented in the ‘‘survival’’ package in the
software program R, were used to explore the
relationship between Cpre-infusion,max and PFS for
CASTOR and POLLUX using P-splines. The
respective control groupswere used as a reference
level for calculating relative hazard. The expo-
sure–safety relationship was explored on the
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basis of exposure quantiles of Cpost-infusion,max
and their corresponding95%confidence interval
for the selected AEs and Cmax,1st for IRRs.
RESULTS
Patient and Disease Characteristics
The population PK dataset included 4426 mea-
surable samples from 694 patients (POLLUX,
n = 282; GEN503, n = 44; EQUULEUS, n = 128;
CASTOR, n = 240), 684 of whom received dara-
tumumab 16 mg/kg. A small proportion (2.5%)
of the samples were below the LLOQ of
0.2 lg/mL for daratumumab and excluded from
the population PK analysis. Descriptive statistics
of baseline continuous and categorical patient
and disease covariates are summarized in Sup-
plemental Table 3 and Supplemental Table 4,
respectively.
Comparison of PK of Daratumumab
Following Monotherapy and Combination
Therapy Regimens
Regardless of the background regimen in the
treatment combination, daratumumab concen-
trations were similar to those in the
monotherapy studies (Supplemental Fig. 1). The
similar PK of daratumumab between the
monotherapy and combination therapy studies
suggested that the small-molecule combina-
tions would not impact daratumumab PK. As in
the monotherapy studies, concentration–time
data for daratumumab in combination regi-
mens were adequately described by a two-com-
partment population PK model with parallel
linear and non-linear Michaelis–Menten elimi-
nations. The parameter estimates of the final
covariate model are presented in Supplemental
Table 5. Exposure to daratumumab was similar
between monotherapy and combination thera-
pies. The average predicted Cpre-infusion,max was
632.8 lg/mL following combination therapy
with daratumumab using the POLLUX dosing
schedule (after 8 weekly infusions) and
667.0 lg/mL for the CASTOR schedule (after
9 weekly infusions) versus 530.7 lg/mL follow-
ing daratumumab monotherapy (after 8 weekly
infusions). The model-derived mean [± stan-
dard deviation (SD)] half-life associated with
linear elimination was 23.3 ± 11.8 days in the
combination studies, assuming the standard
(POLLUX-like) dosing schedule, compared with
18.0 ± 9.0 days in the monotherapy studies.
Consistent with the monotherapy studies,
steady state levels of daratumumab were
Fig. 1 Model-based simulation of daratumumab clearance versus time using POLLUX (a) and CASTOR (b) dosing
schedules. The red line represents total clearance, and the blue line represents linear clearance. The blue shaded region
delineates the 95% CI for linear clearance. Arrows represent dosing events. CI conﬁdence interval
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reached at approximately 5 months into the
every-4-week (Q4W) dosing period. The total
clearance of daratumumab decreased over time
and approached the non-specific linear clear-
ance after approximately 8 weeks under the
standard dosing schedule (Fig. 1a) as well as the
different dosing schedule used in the CASTOR
study (Fig. 1b). Total clearance continued to stay
close to linear clearance during the Q4W dosing
period, suggesting that target saturation was
maintained. During the Q4W dosing period,
concentrations consistent with 99% target sat-
uration were maintained at trough concentra-
tions in more than 90% of patients treated with
the recommended dosing schedule (Fig. 2a) and
the CASTOR dosing schedule (Fig. 2b).
Effects of Patient and Disease
Characteristics on Daratumumab
Exposure
The effects of patient and disease characteristics
on the estimated Cpre-infusion,max were similar to
or smaller than those estimated using the model
based on the monotherapy studies [14] (Table 1)
and were similar regardless of dosing schedule
(data not shown). Consistent with the results
from the monotherapy studies, all of the inves-
tigated covariate effects were within 25% of the
reference value. Clearance and volume of dis-
tribution of daratumumab increased with
increasing body weight; however, daratumumab
exposure differed by less than 20% across
patients with varied body weights when dara-
tumumab was administered on a milligram per
kilogram basis. Daratumumab exposure was
approximately 23% lower in patients with IgG-
type MM compared with those who had non-
IgG MM. No dose adjustments are recom-
mended on the basis of the presence of the IgG
myeloma subtype [14].
Relationship Between Daratumumab
Exposure and Efficacy
An exposure–response analysis on PFS for POL-
LUX and CASTOR was done with their control
groups (Rd and Vd, respectively) as the refer-
ence level to calculate the relative hazard
(Fig. 3a, b). The relative hazard for PFS and
Fig. 2 Target saturation proﬁle of daratumumab at pre-infusion time points for the POLLUX (a) and CASTOR
(b) dosing schedules. For the POLLUX dosing schedule (a), the simulations were performed assuming the dosing schedule
of QW for 8 weeks, Q2W for 16 weeks, and then Q4W thereafter. For the CASTOR dosing schedule (b), the simulations
were performed assuming the dosing schedule of QW for 9 weeks, Q3W for 15 weeks, and then Q4W for 32 weeks
thereafter. The predicted target saturation was calculated as 100 9 C/(KM ? C), where C represents the pre-infusion
(trough) concentration at each time point. Arrows represent dosing events. QW weekly, Q2W every 2 weeks, Q4W every
4 weeks, Q3W every 3 weeks
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Table 1 Effect of covariates on daratumumab exposure: comparison of change relative to reference value of the
Cpre-infusion,max between monotherapy and combination therapies (POLLUX dosing schedule)
Covariate Monotherapy Combination therapies
Renal function
Mild vs. normal 1.15 (0.86–1.54) 0.99 (0.91–1.07)
Moderate vs. normal 0.96 (0.71–1.30) 0.97 (0.89–1.06)
Severe vs. normal 1.00 (0.47–2.12) 1.02 (0.78–1.32)
Hepatic function
Mild vs. normal 0.71 (0.51–0.98) 1.01 (0.91–1.12)
Moderate/severe vs. normal NE 0.95 (0.63–1.41)
Age, years
C 65 vs.\ 65 1.07 (0.84–1.35) 1.06 (0.99–1.13)
C 75 vs.\ 75 1.09 (0.71–1.69) 1.01 (0.90–1.13)
Sex
Male vs. female 0.86 (0.68–1.09) 0.96 (0.90–1.03)
Race
White vs. non-white 0.88 (0.61–1.27) 1.10 (1.01–1.19)
Body weighta, kg
Q3 vs. Q4 1.06 (0.76–1.47) 0.98 (0.90–1.08)
Q2 vs. Q4 0.90 (0.65–1.25) 0.89 (0.81–0.98)
Q1 vs. Q4 0.76 (0.54–1.06) 0.81 (0.74–0.90)
Albumin, g/L
\ 35 vs. C 35 (normal) 0.72 (0.57–0.92) 0.79 (0.74–0.86)
Prior line of therapy
2 vs. 1 NA 0.98 (0.90–1.06)
3 vs. 1 NA 0.97 (0.88–1.07)
[ 3 vs. 1 NA 0.84 (0.75–0.93)
[ 3 vs. B 3 0.83 (0.63–1.11) NA
Refractory status
PI only vs. none NA 0.93 (0.82–1.06)
IMiD only vs. none NA 0.95 (0.84–1.08)
Double vs. none NA 0.92 (0.81–1.05)
Double vs. other 1.08 (0.80–1.46) NA
ECOG status
1 vs. 0 0.88 (0.68–1.15) 0.99 (0.92–1.06)
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depth of response decreased rapidly with
increasing daratumumab exposure based on the
data from POLLUX and CASTOR (data not
shown). When the maximum trough concen-
tration was approximately 250 lg/mL, the risk
compared to the control group was substan-
tially reduced (by approximately 25% for POL-
LUX and CASTOR). When Cpre-infusion,max was
greater than 250 lg/mL, the decline in relative
hazards appeared to slow down, suggesting
limited additional benefit at higher pre-infusion
daratumumab concentrations. The majority of
patients (approximately 75%) approached
maximum effect, indicating that the maximum
clinical benefit on PFS was achieved at the rec-
ommended 16 mg/kg dose and dosing schedule.
Table 1 continued
Covariate Monotherapy Combination therapies
2 vs. 0 0.85 (0.51–1.43) 0.95 (0.82–1.11)
Type of myeloma
IgG vs. non-IgG 0.50 (0.40–0.62) 0.77 (0.73–0.83)
The Cpre-infusion,max for the monotherapy and combination therapies were 530.65 lg/mL (494.6–566.7) and 632.8 lg/mL
(620.0–645.6), respectively
NE not evaluable, Q quantile, NA not applicable because of different grouping for monotherapy and combination
therapy analyses, PI proteasome inhibitor, IMiD immunomodulatory drug, ECOG Eastern Cooperative Oncology Group,
Ig immunoglobulin
a The quantiles of body weight for combination studies were Q1\ 64.6 kg, Q2[ 64.6 to B 75.9 kg, Q3[ 75.9 to
B 88.0 kg, and Q4[ 88.0 kg. The quantiles of body weight for monotherapy studies were Q1\ 63.9 kg, Q2[ 63.9 to
B 78.6 kg, Q3[ 78.6 to B 88.1 kg, and Q4[ 88.1 kg
Fig. 3 Relative hazard of PFS at different predicted maximal trough concentrations for POLLUX (a) and CASTOR (b). The
solid red line is the point estimate, and the gray shaded areas represent the 95% CI. The blue vertical dotted lines separate the
quartiles of Cpre-infusion,max. The control group of each study (Rd in POLLUX and Vd in CASTOR) was used as the reference
(i.e.,Cpre-infusion,max = 0).Cpre-infusion,max up to the 8thQWdose for POLLUX andCASTOR. StratiﬁedCox regressionmodels
based on risk stratiﬁcation of the patients were used to estimate the relative hazard. PFS progression-free survival,CI conﬁdence
interval, Rd lenalidomide and dexamethasone, Vd bortezomib and dexamethasone, QW weekly
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Relationship Between Daratumumab
Exposure and Safety
There was no apparent relationship between
Cpre-infusion,max and any of the examined AEs of
interest including thrombocytopenia, anemia,
neutropenia, and lymphopenia based on data
from the four combination therapy studies
(Table 2). Although the rate of infections of any
grade appeared to increase numerically with
daratumumab exposure, this trend was not
observed for grade 3 or higher infections. Simi-
larly, no association between increasing Cmax,1st
and the incidence of IRRs was identified. Across
all of the studies, two patients were identified as
being positive for anti-daratumumab antibod-
ies, one from POLLUX and one from EQUU-
LEUS; no differences between the PK of these
patients and those without anti-daratumumab
antibodies were discernable.
DISCUSSION
The benefits of adding daratumumab to combi-
nation regimens in the treatment of relapsed or
relapsed and refractory MM necessitate an
understanding of the PK profile of the drug in
these regimens. This population PK analysis
included data from a large number of subjects in
early and late phase,multinational, clinical trials
evaluating the use of daratumumab in combi-
nation therapy for patients withMM. These data
allowed evaluation of important patient-related
covariates across various patient populations and
daratumumab dosing schedules as well as con-
firmation of the findings inmonotherapy studies
that had relatively smaller sample sizes [25].
The PK of daratumumab in combination
with other treatment regimens were consistent
with the PK of daratumumab administered as
monotherapy [12–14].
Daratumumab exposure was similar when
administered with various combination thera-
pies and as monotherapy. The predicted
Cpre-infusion,max (632.8 lg/mL vs 530.65 lg/mL,
respectively) and mean half-life (23 vs 18 days,
respectively) for daratumumab combination
therapy versus monotherapy at the recom-
mended dose and dosing schedule in POLLUX
were similar. Achievement of steady state was
consistently reached at approximately 5 months
into the Q4W dosing period of the standard
daratumumab dosing schedule. Moreover, dara-
tumumab in combination with small-molecule
therapies achieved greater than 99% target satu-
rationat troughconcentrations inmore than90%
of patients following the Q4W dosing regimen.
When the Cpre-infusion,max was above the EC
ORR
90
identified at 274 lg/mL from the monotherapy
studies [12], the ORR was markedly higher com-
pared to those patients withCpre-infusion,max below
274 lg/mL (data not shown).
As observed in the monotherapy studies [14],
no demographic or clinical characteristics were
identified as having a clinically relevant effect on
daratumumab PK. The covariate effects were all
within 25%, and thus, no dose adjustment is
recommended on the basis of these covariates.
Increasing body weight was associated with
increased daratumumab clearance and volume
of distribution; however, daratumumab expo-
sures were consistent across patients’ weight
range, indicating that a body weight-based dose
is reasonable and effective for administration of
daratumumab in combination therapies. Ele-
vated levels of IgG M-protein can lead to
increased clearance of IgG-based monoclonal
antibodies as a result of competition for the
neonatal Fc receptor, which protects IgG from
degradation [26]. Similar to findings observed in
the daratumumabmonotherapy studies [14], the
IgG MM patients had lower concentrations of
daratumumab than the non-IgG MM patients.
However, the difference was only 23%, approxi-
mately half of the magnitude of the difference
observed in monotherapy studies [25], and was
not considered clinically important.
Although most monoclonal antibodies have
a biphasic PK profile with rapid distribution and
slower elimination, individual PK properties of
monoclonal antibodies are unique based on the
biology of their target antigen [27]. The specific
clearance of monoclonal antibodies is affected
by binding to the target antigen, internaliza-
tion, and subsequent intracellular protein cata-
bolism. Fc-mediated effector functions not only
contribute to the mechanism of action of
monoclonal antibodies but also can impact
their clearance. These factors highlight the need
Adv Ther
for PK evaluations of each therapeutic mono-
clonal antibody used for treatment of MM.
The exposure–efficacy analyses suggest that
maximum clinical benefit on PFS has been
attained for the majority of the subjects (approx-
imately 75%) with an acceptable safety profile at
the recommended dose, 16 mg/kg. Target satura-
tion was maintained throughout dosing, even
duringQ4Wdosing. At the recommendeddose of
16 mg/kg, the safety profile was acceptable, and
there was no apparent relationship within the
studied concentration range between drug expo-
sure and IRRs, thrombocytopenia, anemia, neu-
tropenia, and lymphopenia. The overall event
rate of infection (any grade) appeared to increase
with drug exposure, but this trend was not
observed for grade 3 or higher infections.
There are some limitations to this study that
are intrinsic to population PK analyses. Although
a substantial number of MM patients from mul-
tiple clinical trials were utilized for analyses of PK
over time, these analyses were limited by the
schedule of PK sampling that varied slightly in
each study protocol. In addition, data from
clinical trials that utilized different daratu-
mumab combination therapies were pooled for
the analysis, with differences in sample size,
phase of drug testing, and inclusion criteria
between studies. Nevertheless, the PK data from
this study are consistent with previous findings
from daratumumab monotherapy studies and
support the recommended 16 mg/kg dose of
daratumumab in combination therapy.
CONCLUSION
These data support the recommended daratu-
mumab 16 mg/kg dose in combination treat-
ment regimens for patients with MM.
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